EML4 and non-small cell lung carcinoma: As for patients with EML4-ALK(+) NSCLC, with crizotinib resistant mutations, NPM-ALK(+) ALCL patients could benefit in the years to come from second- and third-generation ALK inhibitors alone or in combination with inhibitors of key downstream cell signaling pathways or key regulators of ALK tyrosine kinase activity.